FATE THERAPEUTICS INC. - COMMON STOCK

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

14 Nov 2024 08:54:48 By NetDania Notify

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

12 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

09 Nov 2024 12:30:00 By Nasdaq GlobeNewswire

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

08 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

04 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

02 Oct 2024 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

12 Sep 2024 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

13 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

02 Aug 2024 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors

31 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

02 Jul 2024 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

04 Jun 2024 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

29 May 2024 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

09 May 2024 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

09 May 2024 07:30:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates

06 May 2024 07:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

03 May 2024 15:30:00 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

22 Apr 2024 15:30:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference

03 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

02 Apr 2024 15:01:00 By Nasdaq GlobeNewswire